Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
23 March 2022 | Story André Damons | Photo UFS Photo Archive
Prof Matsabisa
Prof Motlalepula Matsabisa is a professor and Director of Pharmacology at the University of the Free State (UFS)

The Department of Pharmacology at the University of the Free State (UFS) and FARMOVS have teamed up to conduct the first South African Health Products Regulatory Authority (SAHPRA)-approved multicentre controlled clinical trial of a plant-based product, PHELA, on mild to moderate COVID-19 patients.  

According to Prof Motlalepula Matsabisa, professor and Director of Pharmacology at UFS, it is anticipated that the trial will start in early April with each patient being on treatment for 28 days.

“The main purpose of the clinical trial is to confirm that the product can treat COVID-19 and be registered as a medication for this indication. We believe the medication works as an immune modulator to modulate the cytokine storm due to COVID-19 and also restores and normalises the patient’s immune system. We plan to have 250 patients who suffer from mild to moderate COVID-19,” explains Prof Matsabisa. 

This pivotal study, he says, is based on the modification of the World Health Organisation (WHO) Master protocol for clinical trials. The use of FARMOVS, a wholly owned clinical research company of the UFS Bloemfontein campus, for this clinical trial was to implement the collaborative initiatives between UFS and FARMOVS on clinical research, training, and other research projects.

What is PHELA?

Prof Matsabisa, deputy president of the South African Society for Basic and Clinical Pharmacology Society (SASBCP), says the development of PHELA has been under stringent scientific scrutiny for its safety in both preclinical and clinical research. The efficacy of PHELA as both an immune modulator and an anti-SARS-COV-2 has been proven in vitro and in vivo with reproducible results conducted by three independent research institutions and a science council.
The Department of Pharmacology and FARMOVS are collaborating on a number of studies to advance clinical research on African Traditional Medicines (ATM).

On the use of PHELA, Prof Matsabisa explains: “PHELA is a herbal product made of four medicinal plants. Traditionally PHELA has been claimed for use for a historical disease called muyaga, but recently has been scientifically tested and found effective as an immune modulator and benefiting persons with a compromised immune system.
“The PHELA plants are found in most provinces of South Africa and we have cultivated them to control their growth to produce quality raw materials.” 

“The SAHPRA-approved clinical trial will be conducted in the Eastern Cape, Northern Cape and Gauteng. The clinical trial will be conducted by a complement of medical staff and clinicians with vast experience of many active years of clinical trials.
 
“The study, we believe, is a benchmark for all future traditional medicines clinical trial protocols and studies. The studies are expected to start immediately after the product batch manufacturing of the study product, PHELA, is completed and this will be within a month’s time. “A lot of good scientific preclinical safety and efficacy research has gone into the development of the study product for it to reach this stage.

“The efficacy studies have shown convincingly that PHELA is an immune reconstitution product and does have an effect in killing the SARS-COV-2 virus and most of its variants.  PHELA efficacy, therefore, needs to be confirmed through randomised controlled multicentre clinical trials in COVID-19 patients,” Prof Matsabisa says.

Medicinal plants have previously been used to eradicate life-threatening viruses 

Although medicinal plants have been used to combat previous pandemics such as the Spanish flu, avian influenza and others, we still believe rigorous control and efficacy thereof is still to be supported by scientific research and development, says Prof Matsabisa. 

Prof Matsabisa, the current chairperson of the World Health Organisation’s (WHO) Regional Expert Advisory Committee on Traditional Medicines (REACT), adds: “We have better technologies and resources now, which is why we should take the next step in research to promote consumer safety and to offer them effective alternatives. We do the science to aid in building the herbal industry and develop sustained consumer confidence in traditional medicines. 

Africa should lead the way to a healthier future for all
“My vision is for Africa to share our valuable resources with the world by developing, and distributing world-class medicinal solutions. We should develop and strengthen the pharmaceutical local production of well-researched, quality, safe and efficacious African traditional medicines as commercial products. We are more than capable of doing so and now is the time to do it. Numerous discussions have taken place where other African countries will join South Africa in conducting multicentre studies in clinical trials for traditional medicines. 

“We need to develop or create, based on this current collaborative work with partners like FARMOVS, health centres with a strong focus on African medicines, health products and healing, but in a very strong collaborative initiative with other health systems”, concludes Prof Matsabisa.

Prof Matsabisa was recently awarded a Visiting Professorship at the Beijing University of Chinese Medicine (BUCM) in Beijing, China. He was also recommended to Naledi Pandor, Minister of International Relations and Cooperation, to be part of the India, Brazil and South Africa (IBSA) working group in traditional medicine through his participation in the national department of health technical committee on traditional medicines where he has been appointed by the Minister of Health, Dr Joe Phaahla.

News Archive

Right to Learn cyclists cross the finish line
2017-12-05

 Description: R2L Finish  Tags: cyclists, Right to Learn, Cape Town, Paarl, GivenGain Foundation, donations 

The Right to Learn cycling team are happy and thankful that they have completed
their journey.
Photo: Mike Rose

After a seven-day journey, the Right to Learn cycling team have finally reached their destination. Having travelled for over a 1 000 kilometres from Bloemfontein, they arrived safely in the Paarl on Monday 4 December 2017. During their final stretch, they travelled 130 kilometres from Montagu to Paarl, where they ended the Right to Learn Cycling Tour.
 
Gratitude for support
Asive Dlanjwa, Bloemfontein Campus SRC President, says, “It's been good, it's been tough, and it’s been an amazing journey.” He expressed his gratitude to everyone who has been supporting them throughout the journey. “Thank you so much for every cent that you have given, for every prayer, and every thought.”
 
Thulasizwe Mxenge, one of the guest cyclists from Johannesburg, says, “Asive had informed us that most students struggle with access to higher education, and we saw the need to assist and take part in the initiative.” He says the journey was tough, because they had to cycle for about five hours every time they went on the road. “I’m very tired but also happy to have completed the journey.”

Donations received
Since the beginning of the Right to Learn initiative, they have managed to raise R80 000 through corporate giving, R15 584 on Dlanjwa’s GivenGain page, and $500 (about R6 845) from the GivenGain Foundation as part of the #GivingTuesday Twitter campaign which took place on 28 November 2017.
 
Annamia van den Heever, Director: Institutional Advancement, says, “Congratulations to Asive and the team!  It has been an absolute pleasure to work with such positive and passionate young people.” She also thanked all donors to the Right to Learn campaign for their support, saying it will ensure that talented students who cannot afford university fees will have access to the UFS next year. “We are hoping that more people will donate now that the tour has been successfully completed. There is no better Christmas gift,” she says.

Dlanjwa says, “We are committed to helping learners who are coming to the UFS next year. The trip was amazing and I feel stronger than I expected. I’d definitely do this again.”
The community is still encouraged to donate towards the initiative, using the following details:

EFT transaction:
Please use the following bank details:
Bank: ABSA Bank
Account Number: 1570850721
Branch Code: 632005
Account Type: Cheque
Reference: R2L: Right to Learn
Send the proof of payment to Rinda Duraan: duraanmj@ufs.ac.za

Debit order: Download the form and email it to Rinda Duraan

All donations are tax deductible in terms of South African income tax legislation.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept